Cytovance Biologics, a U.S.-based Contract Development and Manufacturing Organization (CDMO), announced the launch of its in-house formulation development services, significantly expanding its service ...

The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation ...

SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 17, 2025 / Bora Biologics is set to showcase its innovative Allosteric Formulation Platform at the Festival of Biologics 2025, demonstrating ...

ALBANY, N.Y.--(BUSINESS WIRE)--Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

The "Subcutaneous Biologics Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Biologic, Type of Therapy, End User, Payment Method Employed, Therapeutic Area, Drug Delivery ...